Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eliano P Navarese

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Evidence-Based Medicine|October 23, 2015
Longer dual antiplatelet therapy (DAPT) after percutaneous coronary intervention has higher anti-ischaemic efficacy than shorter DAPT but is associated with more frequent bleedingEliano P Navarese
European Heart Journal|September 21, 2021
Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromesEliano P Navarese, Felicita Andreotti
Atherosclerosis|March 2, 2016
Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literatureMichalina Kołodziejczak, Eliano P Navarese
Mayo Clinic Proceedings|August 6, 2019
In reply-"Real World" TAVR: Data in Constant FluxEliano P Navarese, Felicita Andreotti
Atherosclerosis|August 29, 2018
PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agentEliano P Navarese, Paolo Raggi
JACC. Cardiovascular Interventions|February 11, 2026
Bleeding in MI-Related Cardiogenic Shock: From Descriptive Mapping to Causal EvidenceEliano P Navarese, Dean J Kereiakes
Journal of the American College of Cardiology|July 29, 2017
Striking the Balance Between Benefits and Costs of Ticagrelor Beyond 1 Year After Myocardial InfarctionEliano P Navarese, Jan G P Tijssen
JACC. Advances|June 28, 2024
Integrating Pharmacological Features to Personalized Models With Statin Therapy: A Glimpse Into the Future?Eliano P Navarese, Marta Casula, Gavino Casu
Kardiologia Polska|February 19, 2026
Health systems at a crossroads: The strategic necessity of AI-supported heart failure careJacek Kubica, Eliano P Navarese, Ryszard Piotrowicz
European Journal of Preventive Cardiology|May 20, 2026
Revisiting the ISCHEMIA trial data through non-linear machine learning modellingEliano P Navarese, Gregg W Stone, Felicita Andreotti
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Evidence-Based Medicine|October 23, 2015
Longer dual antiplatelet therapy (DAPT) after percutaneous coronary intervention has higher anti-ischaemic efficacy than shorter DAPT but is associated with more frequent bleedingEliano P Navarese
European Heart Journal|September 21, 2021
Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromesEliano P Navarese, Felicita Andreotti
Atherosclerosis|March 2, 2016
Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literatureMichalina Kołodziejczak, Eliano P Navarese
Mayo Clinic Proceedings|August 6, 2019
In reply-"Real World" TAVR: Data in Constant FluxEliano P Navarese, Felicita Andreotti
Atherosclerosis|August 29, 2018
PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agentEliano P Navarese, Paolo Raggi
JACC. Cardiovascular Interventions|February 11, 2026
Bleeding in MI-Related Cardiogenic Shock: From Descriptive Mapping to Causal EvidenceEliano P Navarese, Dean J Kereiakes
Journal of the American College of Cardiology|July 29, 2017
Striking the Balance Between Benefits and Costs of Ticagrelor Beyond 1 Year After Myocardial InfarctionEliano P Navarese, Jan G P Tijssen
JACC. Advances|June 28, 2024
Integrating Pharmacological Features to Personalized Models With Statin Therapy: A Glimpse Into the Future?Eliano P Navarese, Marta Casula, Gavino Casu
Kardiologia Polska|February 19, 2026
Health systems at a crossroads: The strategic necessity of AI-supported heart failure careJacek Kubica, Eliano P Navarese, Ryszard Piotrowicz
European Journal of Preventive Cardiology|May 20, 2026
Revisiting the ISCHEMIA trial data through non-linear machine learning modellingEliano P Navarese, Gregg W Stone, Felicita Andreotti
Pageof 11